DSIP dosage in the research — the numbers the experiments used, and nothing more

Before the numbers

This page reads how DSIP was dosed in studies. It is not a protocol and carries no instructions for any person. DSIP is not an approved medicine, there is no validated human dose, and the studies below used very different amounts in very different species — so the numbers describe experiments, not a recommendation.

In plain terms: most human DSIP work used a single small intravenous amount tied to body weight, given in a clinic for research. Animal studies used a wide spread of amounts and delivery methods. One genuine oddity matters for reading any DSIP dosage figure — the peptide follows a parabolic curve, where a middling amount can do more than a large one, so 'more' is not reliably 'stronger.' Everything here is third-person description of published research.

DSIP dosage in human studies

Across the human research, one figure recurs: 25 nmol/kg of body weight, given intravenously, was the dose used in the chronic-insomnia sleep studies and the stress-hormone work ^[2][4]. It is the most frequently used human research dose in the DSIP literature, administered in a research setting, not self-administered. The double-blind insomnia study used the same 25 nmol/kg intravenous dose and still characterized the resulting benefit as modest ^[18].

No dose here should be read as a target. These were single research administrations under study conditions, and the broader literature provides no validated human dosing standard, no titration schedule, and no pharmaceutical-grade product against which any amount could be measured.

DSIP peptide dosage across animal models

The animal DSIP peptide dosage spread is wide because the questions differed. Rat growth-hormone studies used 0.1-10 micrograms given into the brain, with a minimal effective amount around 0.1 microgram ^[9]. The mouse longevity work used the Deltaran preparation at roughly 100 µg/kg, given under the skin for five consecutive days each month ^[5]. Rat liver stress-protection used 40 µg/kg into the abdominal cavity, with the lowest dose most effective and the protective effect lost at the highest ^[14]. These figures are reported here to characterize the research, not to scale to anyone.

The parabolic dose-response is the thread to hold: in several of these studies the intermediate dose outperformed the high one ^[7][14], which is precisely why animal numbers cannot be read as a ladder where bigger is better.

DSIP half life and why it shapes the dosing question

DSIP clears the body fast. An enzyme-immunoassay metabolic-clearance study in dogs, monkeys, and rats reported a plasma half-life on the order of only a few minutes, attributed to rapid breakdown by enzymes and plasma proteins ^[17]. There is no validated human pharmacokinetic profile at all. The full DSIP half life discussion — what that short window implies, and why analogs were engineered around it — has its own DSIP half life page.

Routes studied, including the dsip peptide nasal spray question

DSIP has been delivered several ways in research: intravenously in humans and animals, into the brain's ventricles in rodents, under the skin in cats and mice, and intranasally in a rat neuroprotection study ^[1][5][9]. On the dsip peptide nasal spray question specifically, the nasal route appears in animal neuroprotection research, but no controlled human study validates an intranasal DSIP product, dose, or formulation, so the nasal-spray framing common online is not backed by clinical evidence. As a short peptide, DSIP is subject to rapid enzymatic degradation, which is part of why structurally modified analogs were developed ^[7].